NEWSROOM
News & Stories
Newsroom
Press Releases
New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint and BluePrint Across Breast Cancer Patient Populations
IRVINE, CA, AMSTERDAM, NETHERLANDS – 30 November 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the presentation of extensive new data at the upcoming 2017 San Antonio Breast Read More
Agendia’s MammaPrint Breast Cancer Risk-of-Recurrence Test Obtains Favorable Final Payment Determination from CMS for New, Unique Category 1 CPT Code
CMS established the 2018 payment rate for MammaPrint’s new CPT code 81521 thus securing continued access to MammaPrint for Medicare/Medicaid beneficiaries The new determination and increased allowance follows an impressive Q3 which saw MammaPrint’s U.S. Read More
AJCC Confirms MammaPrint’s Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update
Update clarifies that the patient and clinician may choose any genomic profile or multigene panel based on available clinical evidence at the time of treatment In line with recent publications from NEJM and ASCO, the Read More
